Speciality Medicines Ltd. IPO
IPO Timeline
-
20 Mar 2026Bidding Starts
-
24 Mar 2026Bidding Ends
-
25 Mar 2026Allotment Finalization
-
30 Mar 2026Listing
About Speciality Medicines Ltd.
We are engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases.We offer a diverse portfolio of specialty pharmaceutical products, focusing on various therapeutic areas such as oncology, immunology, neurology, and rare diseases. Our products which are offered in such areas are available in a wide range of dosage forms like Tablets, Capsules, Cream, Syrups, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet and Suspension. We operate through two integrated business models: (a) Manufacturing, through contract manufacturing basis, of approved finished formulations and distribution internationally and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers.
Speciality Medicines Ltd. IPO Reservation
| Investors Category | Shares Offered |
|---|---|
| Market Makers | 1,50,000 (11.79%) |
| Non Institutional Investors | 10,78,000 (84.75%) |
| Qualified Institutional Buyers (QIBs) | 44,000 (3.46%) |
| Retail Individual Investors (RIIs) | 10,78,000 (84.75%) |
Speciality Medicines Ltd. Financial Information
| Year End | Revenue | PAT | Reserves & Surplus |
|---|---|---|---|
| 31 Mar 2026 | 76.11 Cr | 13.03 Cr | 62.41 Cr |
| 31 Mar 2025 | 58.54 Cr | 8.61 Cr | 23.98 Cr |
| 31 Mar 2024 | 27.66 Cr | 2.93 Cr | 9.95 Cr |
Speciality Medicines Ltd. Background
-
2021Incorporation of our company viz. “Speciality Medicines Private Limited”.
Our Company shifted its operation to Mumbai, Maharashtra, India
-
2022Our Company was recognized as Start-up by Department for Promotion of Industry and Internal Trade
-
2023Our Company received certificate as an eligible business by Inter-Ministerial Board to avail Income Tax benefits under Section 80-IAC of the Income Tax Act, 1961.
-
2024Conversion of our Company from Private Limited to Public Limited Company.
1. Setting up of Research and Development (R&D) Center
2. Product registration and Development in the international markets
3. Funding for Marketing and Brand Promotion Activities Promotional Activities
4. To Meet Working Capital Requirements
5. General Corporate Purposes
| Pricing Details | BSE | NSE |
|---|---|---|
| Issue Price | ₹ 124.00 | - |
| Open | ₹ 124.00 | - |
| Low | ₹ 124.00 | - |
| High | ₹ 129.50 | - |
| Last Trade | ₹ 125.90 | - |
1. Parth Goyani
2. Sumit Goyani
India is the largest provider of generic drugs globally, accounting for approximately 20% of the global supply by volume and contributes over 60% of the global vaccine demand. As of 2024, India is home to over 3,000 pharmaceutical companies and more than 10,000 manufacturing facilities, including ... Read more
Phone no:7405452730
FAQs
When does Speciality Medicines Ltd. IPO opens and closes?
Speciality Medicines Ltd. IPO opens from 20th March to 24th March 2026.What is the size of Speciality Medicines Ltd. IPO?
The size of the Speciality Medicines Ltd. IPO is ₹15.77 Cr.What is the price range of Speciality Medicines Ltd. IPO?
The price range of Speciality Medicines Ltd. IPO is at ₹117 to ₹124 per share.What is the minimum investment and lot size required for the Speciality Medicines Ltd. IPO?
The minimum investment required is ₹1,24,000 and minimum lot size is 1000 shares.When is Speciality Medicines Ltd. IPO listing date?
The Speciality Medicines Ltd. IPO will be listed on 30th March 2026.What is the objective of Speciality Medicines Ltd. IPO?
1. Setting up of Research and Development (R&D) Center2. Product registration and Development in the international markets
3. Funding for Marketing and Brand Promotion Activities Promotional Activities
4. To Meet Working Capital Requirements
5. General Corporate Purposes
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article


Click it and Unblock the Notifications